Full Breakdown
Jason Collins' Battle Against Stage 4 Glioblastoma: Seeking Hope in Singapore
12/15/2025, 10:26:06 PM
Overview of Jason Collins' Diagnosis and Treatment
Jason Collins, a former National Basketball Association (NBA) player and the first openly gay athlete in a major U.S. professional sports league, has been diagnosed with stage 4 glioblastoma multiforme (GBM), the most aggressive form of brain cancer. Collins announced his diagnosis on August 30, 2023, revealing that he is undergoing experimental treatment in Singapore, having received approval for the treatment within 48 hours. The urgency of his situation was underscored by medical advice indicating he could face death within six weeks to three months without intervention.
The Experimental Treatment: EDV
Collins is receiving a novel treatment involving EnGeneIC Dream Vectors (EDVs), developed by the Australian biopharmaceutical company EnGeneIC. This method utilizes a targeted delivery system designed to transport therapeutic agents directly to the tumor, bypassing the blood-brain barrier. Collins described the treatment as “high-tech, science fiction type stuff,” emphasizing its innovative nature. The treatment is currently available under compassionate use, aimed at patients with limited options and low survival rates.
Background and Context
Collins began experiencing troubling symptoms in August 2023, which led to a CT scan that revealed a baseball-sized tumor in his brain. He noted that the tumor's aggressive growth rate was alarming, as it was expanding at a rate of 30 percent, significantly higher than the 20 percent threshold considered severe. His previous treatment options in the United States were ineffective due to the tumor's unique genetic makeup.
Official Statements & Responses
In a letter published with ESPN, Collins expressed his determination to fight the disease, stating, “I’m unafraid to break through a wall or try to do everything possible.” He acknowledged the emotional support from his family and fans, which bolsters his resolve. EnGeneIC's co-founders noted that patients typically show clinical benefits during the first cycle of treatment, with improvements in cognitive abilities reported.
Criticism & Opposition
While Collins' treatment has garnered support, some critics have raised concerns about the accessibility and affordability of such experimental therapies. Djeng Shih Kien, CEO of the Singapore Institute of Advanced Medicine, indicated that the goal is to make the treatment affordable if trials prove successful, emphasizing the importance of accessibility in cancer care.
Verbatim Quotes
- “I have a Glioblastoma. It is butterflied. It’s pretty much taken over,” — Jason Collins
- “ “Life is so complicated that the energy that it takes to have negative energy, it’s like, why?” — Jason Collins
- “The goal is to keep fighting the progress of the tumour long enough for a personalised immunotherapy to be made for me, and to keep me healthy enough to receive that immunotherapy once it’s ready,” — Jason Collins
- “I feel good thinking that it might help someone else who gets a diagnosis like this one day.” — Jason Collins
What's Next
Collins is expected to remain in Singapore for approximately seven to eight weeks as he undergoes this experimental treatment. The EDV technology is anticipated to enter clinical trials in Singapore by the end of January 2026, potentially paving the way for broader access to innovative cancer therapies in the future. Collins' journey highlights the intersection of sports, health, and the quest for groundbreaking medical solutions.
